- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Nutraplus starts production of Lumefantrine at Tarapur plant
New Delhi: Pharma firm Nutraplus India has started commercial production of anti-malarial drug Lumefantrine at its new plant at Tarapur in Maharashtra.
"Previously company was engaged in the manufacturing of intermediate of the same drug... and was selling to various pharma companies," Nutraplus India said in a filing to BSE.
Now, it is manufacturing the final end product at the company's new production facilities, it added.
Saying that this adds to the margins for the company, Nutraplus India said: "This is a forward integration and shall result in better margin."
The company expects to achieve full production capacities in next three months in the plant, it added.
"Previously company was engaged in the manufacturing of intermediate of the same drug... and was selling to various pharma companies," Nutraplus India said in a filing to BSE.
Now, it is manufacturing the final end product at the company's new production facilities, it added.
Saying that this adds to the margins for the company, Nutraplus India said: "This is a forward integration and shall result in better margin."
The company expects to achieve full production capacities in next three months in the plant, it added.
Next Story